Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MDS”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Temporarily pausedNCT06630221
What this trial is testing

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Who this might be right for
Myelodysplastic SyndromesChronic Myelomonocytic Leukemia
Abhay Singh, MD MPH 25
Large-scale testing (Phase 3)Study completedNCT03306264
What this trial is testing

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Who this might be right for
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Astex Pharmaceuticals, Inc. 227
Testing effectiveness (Phase 2)UnknownNCT00008164
What this trial is testing

Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia

Who this might be right for
Childhood Langerhans Cell HistiocytosisLeukemiaLymphoma+3 more
Herbert Irving Comprehensive Cancer Center 30
Not applicableEnded earlyNCT00443300
What this trial is testing

Effectiveness of Protected Environment Rooms for AML and MDS

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)WithdrawnNCT01302106
What this trial is testing

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Early research (Phase 1)Ended earlyNCT00923234
What this trial is testing

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic SyndromesAcute Myelogenous Leukemia
Technische Universität Dresden
Early research (Phase 1)Study completedNCT01319864
What this trial is testing

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

Who this might be right for
Relapsed/Refractory AMLRelapsed/Refractory ALLSecondary AML/MDS+3 more
Seattle Children's Hospital 20
Large-scale testing (Phase 3)Study completedNCT03745716
What this trial is testing

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Who this might be right for
MDS
Aprea Therapeutics 154
Not applicableStudy completedNCT02767388
What this trial is testing

Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery

Who this might be right for
Myelodysplastic SyndromeEffects of ChemotherapyMild Cognitive Impairment+6 more
University of Nebraska 45
Early research (Phase 1)Not Yet RecruitingNCT07737769
What this trial is testing

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
University of Michigan Rogel Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT00882102
What this trial is testing

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
M.D. Anderson Cancer Center 43
Early research (Phase 1)Looking for participantsNCT03896269
What this trial is testing

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Who this might be right for
Blasts 10-19 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsHigh Risk Chronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 38
Testing effectiveness (Phase 2)Ended earlyNCT01034657
What this trial is testing

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT05428969
What this trial is testing

Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Who this might be right for
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes+1 more
Faron Pharmaceuticals Ltd 181
Testing effectiveness (Phase 2)Study completedNCT01203722
What this trial is testing

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Who this might be right for
Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 87
Testing effectiveness (Phase 2)Study completedNCT01350245
What this trial is testing

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesBiphenotypic Leukemia+7 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 28
Early research (Phase 1)Looking for participantsNCT06498973
What this trial is testing

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center 43
Testing effectiveness (Phase 2)Looking for participantsNCT06745622
What this trial is testing

Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria
Haisco Pharmaceutical Group Co., Ltd. 47
Testing effectiveness (Phase 2)WithdrawnNCT04985656
What this trial is testing

Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes (MDS)
Takeda
Large-scale testing (Phase 3)UnknownNCT03655145
What this trial is testing

HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyeloproliferative Syndromes+1 more
Assistance Publique - Hôpitaux de Paris 344
Next Page